Skip to content
Open access

TPX2 promotes osteosarcoma progression by conferring ferroptosis resistance through the AURKA/NRF2 signaling axis

Oct 2026 · Journal of Bone Oncology · Vol 61 · 0 citations · 40 references
Medicine

Abstract

Background Ferroptosis has emerged as a potential avenue for cancer therapy; however, the molecular mechanisms regulating ferroptosis resistance in osteosarcoma (OS) remain incompletely understood. This study aimed to investigate the role of targeting protein for Xklp2 (TPX2) in OS progression and ferroptosis, focusing on the aurora kinase A (AURKA)/nuclear factor erythroid 2-related factor 2 (NRF2) signaling axis. Methods OS-related genes were screened from GSE16088 and GSE42352, followed by functional enrichment, protein-protein interaction (PPI), and receiver operating characteristic (ROC) analyses. TPX2 expression and function in OS cells were evaluated via quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, cell counting kit-8 (CCK-8), colony formation, and flow cytometry. Ferroptosis was evaluated in U2OS cells by cellular sensitivity to erastin/RSL3, reactive oxygen species (ROS) accumulation, Fe2+, malondialdehyde (MDA) levels, glutathione (GSH) redox status, and solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidase 4 (GPX4) expression. TPX2 and AURKA interaction in U2OS cells was probed using rescue and co-immunoprecipitation (Co-IP) experiments. The stability and ubiquitination level of NRF2 protein were detected using a cycloheximide (CHX) tracing assay and ubiquitination assay. Potential AURKA phosphorylation sites on NRF2 were further assessed using sequence-based kinase scoring. Results TPX2 was abundantly expressed in OS and facilitated cell proliferation, clonogenicity, and G2-phase advancement. In U2OS cells, TPX2 depletion increased sensitivity to erastin and RSL3, ROS, Fe2+, and MDA levels and decreased GSH/GSSG, SLC7A11, and GPX4, which were partially reversed by ferrostatin-1. TPX2 interacted with AURKA, and rescue studies supported AURKA involvement in TPX2-dependent ferroptosis regulation. AURKA sustained NRF2 protein stability by reducing its ubiquitination and degradation. However, no NRF2 site reached the predefined AURKA scoring threshold. TPX2 overexpression had anti-ferroptotic effects, which were suppressed by NRF2 silencing. Conclusion TPX2 contributes to OS cell proliferation and ferroptosis resistance in U2OS cells through an AURKA/NRF2-associated mechanism. Direct NRF2 phosphorylation by AURKA remains unproven, and the ferroptosis mechanism requires validation in additional OS models.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.